Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIXEL early tocilizumab + dexamethasone prophylaxis after axi-cel
jRCT1041250141Recruiting
- Sponsor
- Kite Pharma
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of tocilizumab and dexamethasone in immune effector cell-associated neurotoxicity syndrome (ICANS) (2 arms), sponsored by Kite Pharma. Primary endpoint: Success rate of severe ICANS prevention. Started Mar 2026; status: recruiting.
02
Drugs
tocilizumabdexamethasone
03
Conditions
immune effector cell-associated neurotoxicity syndrome (ICANS)
Beyond the preview
Go deeper on jRCT1041250141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041250141.